Searched for
KEDAR UPADHYE
Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...- Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps downBiocon announced a leadership change. Siddharth Mittal will step down as Managing Director and Chief Executive Officer on March 31. He will...
- Biocon to make Biocon Biologics a wholly owned subsidiaryBiocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Bioc...
- Biocon Biologics names Kedar Upadhye as new CFOUpadhye will be replace current CFO MB Chinappa who will take up strategic finance role at Biocon Group and will work with Peter Bains, the...
- ReNew becomes first Indian renewable energy firm to refinance dollar-denominated bondsAccording to the statement, the ReNew issued bonds worth USD 525 million in 2019, which were set to mature in 2024. By refinancing the doll...
- Cipla to buy 32.49 per cent stake in solar power firmThe acquisition is in line with the commitment to enhance the share of renewable power sources in its operation and to comply with regulato...
- Demand for Covid drugs down, says Cipla Global CFOThe third wave has been fuelled by the Omicron variant, which is highly infectious yet milder, causing flu-like symptoms such as fever, bod...
- Cipla expects sales of branded generics to cross $1 billion this fiscalCipla's branded generics business reported sales of around ₹6,000 crore in FY21. The drug maker's India business, which consists of prescri...
- Nothing commercial yet on Moderna’s vaccine in India: Kedar Upadhye, Cipla CFOIt did well. During the pandemic, it was the responsibility of the industry to do what one can to service. Parallelly, all life-saving medi...
- Cipla says supply of COVID-19 drug remdesivir catching up with demandBackorders and complaints over low supply started moderating in the second week of May, the drugmaker said, after it began ramping up produ...
- India's demand for COVID-19 drug remdesivir to fall, says CiplaCipla was among the first companies in India to launch a generic version of remdesivir, developed by U.S.-based Gilead Sciences, and as of ...
- Indian demand for COVID-19 drug remdesivir rising sharply: CiplaRemdesivir was developed by U.S. drugmaker Gilead Sciences Inc, which cut its 2020 revenue forecast last month, citing lower-than-expected ...
- India's shortage of remdesivir is easing, Goa plant to ramp up production: CiplaRemdesivir, made by U.S.-based Gilead Sciences Inc, has been in high demand globally, and a handful of companies including Cipla are author...
- No data integrity or repeat observations in the Form 483 we received: Kedar Upadhye, CiplaWe are in the process of drafting a very robust response to each of the observations in the Form 483.
- Avenue Therapeutics buy will allow Cipla to enter specialty hospital business in US: Kedar UpadhyeWe are happy with the acceleration of the US pipeline, says Cipla’s Global CFO.
- Cipla trying to create a healthcare ecosystem in India: Umang Vohra“We are happy with our Q1 numbers in a tough environment.”
- Cipla targets $1-billion revenues from domestic market in FY19The company reported revenues of Rs 15,219 crore, growing 6 per cent, with income from the India operations seeing a 6.3 per cent jump at R...
- US pathway for respiratory is going to be a little bit different: Kedar Upadhye of Cipla"We will operate in across the channels and yes we have a good partner and we believe we will get our fair share of the market."
- Cipla appoints Kedar Upadhye as Global CFOUntil recently, Kedar was Vice President, Global Generics Finance and Head of Investor Relations in Dr Reddy's Laboratories, Cipla said in ...
- Cipla hires Kedar Upadhye from Dr. Reddy's as global CFOCipla said in a June 8 announcement to stock exchanges, Kedar Upadhye will be joining the organization as its Global chief financial office...
Load More
